Estrogen Plus Progestin and Risk of Venous Thrombosis

Top Cited Papers
Open Access
Abstract
Venous thrombosis (VT), including deep vein thrombosis (DVT) and pulmonary embolus (PE), is a common disorder with an incidence of about 1 to 2 per 1000 person-years among adults.1 The risk of VT is higher with older age, in men compared with women, in blacks compared with whites, and in obese individuals, but VT is generally not associated with other classic atherogenic risk factors.2-4 Postmenopausal hormone therapy, such as estrogen with or without progestin, and selective estrogen-receptor modulators (tamoxifen and raloxifene) are associated with a 2- to 3-fold increased risk of VT.5-7